Johanna M. Schafer

Johanna M. Schafer

Auto-generated profile, based on publicly available information

Johanna M. Schafer

Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center–The James, Columbus, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Science Immunology
Verified
Journal Article
Closed access
HKHyunwoo Kwon
Hyunwoo Kwon
JSJohanna M. Schafer
Johanna M. Schafer
NSNo-Joon Song
No-Joon Song
SKSatoshi Kaneko
Satoshi Kaneko
ALAnqi Li
Anqi Li
ZLZihai Li
Zihai Li
Sex bias exists in the development and progression of nonreproductive organ cancers, but the underlying mechanisms are enigmatic. Studies so far have focused largely on sexual dimorphisms in cancer biology and socioeconomic factors. Here, we establish a role for CD8 + T cell–dependent antitumor immunity in mediating sex differences in tumor aggressiveness, which is driven by the gonadal androgen but not sex chromosomes. A male bias exists in the frequency of intratumoral antigen-experienced Tcf7 /TCF1 + progenitor exhausted CD8 + T cells that are devoid of effector activity as a consequence of intrinsic androgen receptor (AR) function. Mechanistically, we identify a novel sex-specific regulon in progenitor exhausted CD8 + T cells and a pertinent contribution from AR as a direct transcriptional transactivator of Tcf7 /TCF1. The T cell–intrinsic function of AR in promoting CD8 + T cell exhaustion in vivo was established using multiple approaches including loss-of-function studies with CD8-specific Ar knockout mice. Moreover, ablation of the androgen-AR axis rewires the tumor microenvironment to favor effector T cell differentiation and potentiates the efficacy of anti–PD-1 immune checkpoint blockade. Collectively, our findings highlight androgen-mediated promotion of CD8 + T cell dysfunction in cancer and imply broader opportunities for therapeutic development from understanding sex disparities in health and disease.

21 June 2023 in Nature
Verified
Journal Article
Closed access
PDF file
HAHany Abdel-Hafiz
Hany Abdel-Hafiz
JSJohanna M. Schafer
Johanna M. Schafer
XCXingyu Chen
Xingyu Chen
TXTong Xiao
Tong Xiao
TGTimothy D. Gauntner
Timothy D. Gauntner
DTDan Theodorescu
Dan Theodorescu

11 March 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
JSJohanna M. Schafer
Johanna M. Schafer
BLBrian Lehmann
Brian Lehmann
PGPaula I. Gonzalez-Ericsson
Paula I. Gonzalez-Ericsson
CMClayton B. Marshall
Clayton B. Marshall
JBJ. Scott Beeler
J. Scott Beeler
JPJennifer A. Pietenpol
Jennifer A. Pietenpol
This study demonstrates the potential utility of BET and MEK inhibitors for advanced MYCN-expressing triple-negative breast cancer.

31 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LRLindsay N. Redman-Rivera
Lindsay N. Redman-Rivera
TSTimothy M. Shaver
Timothy M. Shaver
HJHailing Jin
Hailing Jin
CMClayton B. Marshall
Clayton B. Marshall
JSJohanna M. Schafer
Johanna M. Schafer
JPJennifer A. Pietenpol
Jennifer A. Pietenpol
P53 is mutated in over half of human cancers. In addition to losing wild-type (WT) tumor-suppressive function, mutant p53 proteins are proposed to acquire gain-of-function (GOF) activity, leading to novel oncogenic phenotypes. To study mutant p53 GOF mechanisms and phenotypes, we genetically engineered non-transformed and tumor-derived WT p53 cell line models to express endogenous missense mutant p53 (R175H and R273H) or to be deficient for p53 protein (null). Characterization of the models, which initially differed only by TP53 genotype, revealed that aneuploidy frequently occurred in mutant p53-expressing cells. GOF phenotypes occurred clonally in vitro and in vivo, were independent of p53 alteration and correlated with increased aneuploidy. Further, analysis of outcome data revealed that individuals with aneuploid-high tumors displayed unfavorable prognoses, regardless of the TP53 genotype. Our results indicate that genetic variation resulting from aneuploidy accounts for the diversity of previously reported mutant p53 GOF phenotypes.

4 July 2022 in iScience
Verified
Journal Article
Open access
JSJohanna M. Schafer
Johanna M. Schafer
TXTong Xiao
Tong Xiao
HKHyunwoo Kwon
Hyunwoo Kwon
KCKatharine Collier
Katharine Collier
YCYuzhou Chang
Yuzhou Chang
ZLZihai Li
Zihai Li
The cancer research field is finally starting to unravel the mystery behind why males have a higher incidence and mortality rate than females for nearly all cancer types of the non-reproductive systems. Here, we explain how sex – specifically sex chromosomes and sex hormones – drives differential adaptive immunity across immune-related disease states including cancer, and why males are consequently more predisposed to tumor development. We highlight emerging data on the roles of cell-intrinsic androgen receptors in driving CD8+ T cell dysfunction or exhaustion in the tumor microenvironment and summarize ongoing clinical efforts to determine the impact of androgen blockade on cancer immunotherapy. Finally, we outline a framework for future research in cancer biology and immuno-oncology, underscoring the importance of a holistic research approach to understanding the mechanisms of sex dimorphisms in cancer, so sex will be considered as an imperative factor for guiding treatment decisions in the future.

1 June 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
VKVadim S Koshkin
Vadim S Koshkin
JSJohanna M. Schafer
Johanna M. Schafer
ESEmilie Scherrer
Emilie Scherrer
CBChristine Boyiddle
Christine Boyiddle
NSNaomi R.M. Schwartz
Naomi R.M. Schwartz
ECEmily Chan
Emily Chan
PURPOSE: The aim of this study was to assess the prevalence of human epidermal growth factor receptor 2 (HER2) protein expression and ERBB2 gene amplification in a large cohort of tumor samples from patients with advanced urothelial carcinoma (UC). MATERIALS AND METHODS: Testing was performed on formalin-fixed, paraffin-embedded tissue from commercially sourced primary advanced or metastatic UC using an anti-HER2/neu (4B5) rabbit monoclonal antibody immunohistochemistry (IHC) assay (detects HER2 protein) and HER2 dual in situ hybridization (DISH) DNA probe cocktail assay (detects ERBB2 gene and the centromere of its residing chromosome 17). The HER2 clinical status was classified as HER2-zero (IHC 0), HER2-low (IHC 1+ or IHC 2+/DISH nonamplified), or HER2-positive (IHC 2+/DISH amplified or IHC 3+). RESULTS: Of the 2,024 UC samples, HER2 protein expression was IHC 0 for 962 (47.5%), IHC 1+ for 297 (14.7%), IHC 2+ for 498 (24.6%), and IHC 3+ for 267 (13.2%). The percentage of HER2-expressing tumors (IHC 1+, 2+, and 3+) was similar between primary (52.2%, 1,028/1,968) and metastatic UC samples (60.7%, 34/56; P = .26). The ERBB2 gene was amplified in 235 cases (11.6%), including 2.7%/3.7%/9.6%/56.2% scored as IHC 0/1+/2+/3+, respectively. Overall, HER2 clinical status was HER2-zero for 962 UC tissue samples (47.5%; 95% CI, 45.4 to 49.7), HER2-low for 747 (36.9%; 95% CI, 34.8 to 39.0), and HER2-positive for 315 (15.6%; 95% CI, 14.0 to 17.2). CONCLUSION: We observed that more than 50% of 2,024 advanced UC tumors demonstrated some degree of HER2 protein expression detected using a standardized IHC method, whereas about 12% of specimens had ERBB2 gene amplification, including about 3% of those scored as either IHC 0 or 1+. Continued development of optimized and standardized HER2 testing methods is warranted to identify patients with HER2-expressing UC who may benefit from novel HER2-targeting therapies.